Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Recruiting × MCRC × regorafenib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Colorectal Neoplasms 10 Carcinoma, Hepatocellular 6 Rectal Neoplasms 2 Liver Neoplasms 2 Glioblastoma 2 Colonic Neoplasms 2 Uterine Cervical Neoplasms 1 Stomach Neoplasms 1 Squamous Cell Carcinoma of Head and Neck 1 Small Cell Lung Carcinoma 1 Sarcoma, Ewing 1 Rhabdomyosarcoma 1 Recurrence 1 Patient Compliance 1 Pathologic Complete Response 1 Ovarian Neoplasms 1 Osteosarcoma 1 Neoplasms 1 Neoplasm Metastasis 1 Multiple Myeloma 1 Microsatellite Stable Metastatic Colorectal Cancer 1 Meningioma 1 Melanoma 1 MCRC 1 Lymphoma, Non-Hodgkin 1 Lung Neoplasms 1 Liver Metastases 1 Leiomyosarcoma 1 Histiocytoma, Malignant Fibrous 1 Hematologic Neoplasms 1

Interventions

tislelizumab 1 regorafenib 1 Trace amine-associated receptor 1 1 Thymalfasin 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06829355 2025-02-17

THYMI

Beijing Friendship Hospital

Phase 2 Recruiting

MCRC

Data powered by HemOnc (CC BY 4.0) Colophon ⚡